Key result
Aortic root thrombosis shows no association with composite adverse events or mortality in LVAD patients.
Why the study?
Aortic root thrombosis may be under-recognized in LVAD patients, potentially leading to cardiac and end-organ damage.
Does the presence of aortic root thrombosis increase the risk of adverse composite clinical outcomes or mortality in patients with left ventricular assist devices?
Cohort (n=44)
No
Does the presence of aortic root thrombosis increase the risk of adverse composite clinical outcomes or mortality in patients with left ventricular assist devices?
p-value: p=0.276
Aortic root thrombosis is a frequent finding (45%) in LVAD patients on echocardiography but was not associated with a significant increase in mortality or composite adverse events in this small cohort.
Aortic root thrombosis should not yet alter LVAD management or surveillance; leaves open prospective evaluation of its clinical relevance.
Background: Aortic root thrombosis (ART) in left ventricular assist device (LVAD) patients has gained attention due to potential clinical consequences. This study aims to assess the clinical outcomes associated with ART in LVAD patients. Methods: We retrospectively evaluated adult patients who received LVAD implants at our center between January 2020 and March 2022. Pre-operative data, including demographics, laboratory values, and echocardiographic assessments, were similar between the ART and non-ART groups. Composite outcomes such as cerebrovascular events, pump thrombosis, myocardial infarction, embolic events, bleeding, right ventricular (RV) failure, and mortality post-discharge were examined. Results: The study included 44 outpatients (36 HeartMate 3, 8 HeartWare). ART was identified in 20 patients (45%) post-discharge. The "no ART" group had a mean age of 47±10 years (23 of 24 patients were male, 95.8%), while the "ART" group had a mean age of 48±12 years (15 of 20 patients were male, 75%), with no significant age difference (p>0.05). Thrombosis occurred at a median of 59 days post-implantation, primarily affecting the non-coronary cusp in 50% of the ART group. The median follow-up period was 416 days. No significant differences were found in composite outcomes (p=0.276), mortality (p=0.814), bleeding (p=0.808), or RV failure (p=0.197). Conclusion: ART may be under-recognized in LVAD patients, potentially leading to cardiac and end-organ damage. While ART does not significantly impact mortality, it emphasizes the need for careful management of LVAD patients.
No takes yet. Share an insight, caveat, or question.
Karahan et al. (2026) conducted a cohort in End-stage heart failure with LVAD implants (n=44). Aortic root thrombosis (ART) vs. No aortic root thrombosis was evaluated on Composite outcomes (cerebrovascular events, pump thrombosis, myocardial infarction, and embolic events) (p=0.276). Aortic root thrombosis, identified in 45% of LVAD patients, did not significantly impact the incidence of composite adverse outcomes (p=0.276) or mortality (p=0.814) compared to patients without thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: